the Convention [8] . PFOA is also the subject of a restriction proposal according to Annex XVII of the European REACH regulation [9] . Other long-chain PFASs are also the subject of risk management option analysis within the context of REACH [10] .
Humans can be exposed to PFASs via oral (food, drinking water, dust or soil ingestion), dermal (contact with consumer products, e.g. all-weather clothing or textiles) or inhalative (contaminated air) routes of exposure. However, the main source of human exposure is food, with fish and seafood having been identified as major contributors. Additionally, frying and cooking in non-stick cookware and food packaged in repellentcoated material might reflect additional sources for PFASs in foodstuffs [11] . Other contributors to human PFASs exposure are some types of paper or cardboard containing surface coatings with large amounts of PFASs. Thus, food like microwave popcorn can be contaminated due to the migration of PFASs after heating [12] .
PFASs have been shown to be easily absorbed but only poorly eliminated by experimental animals. The longer chain compounds are not well metabolised in the organism and undergo enterohepatic circulation [13] . PFASs primarily bind to proteins and can thus accumulate in different body compartments. High concentrations can be found in the blood, liver, kidneys and spleen, but also in the testes and brain [14] . For example, more than 90% of perfluorooctanoic acid (PFOA) binds to serum albumin [15] . After absorption and distribution via blood, PFOA is eliminated as free carboxyl acid primarily via urine and secondarily via faeces, with urinary excretion decreasing with increasing chain-length. In rodents, 100% of the short-chain perfluorohexanoic acid (PFHxA) is eliminated within 24 hours via urine [14] .
Studies conducted on experimental animals have determined the half-lives of different PFASs to be short, while the results of human studies, in contrast, indicate considerably longer half-lives. The estimated mean elimination half-lives in human serum are 5.4 years for PFOS, 3.8 years for PFOA and 8.5 years for perfluorohexane sulphonate (PFHxS) based on studies of a highly exposed occupational cohort [16] .
PFASs have been identified to lead to adverse health effects. Especially for PFOS and PFOA, extensive toxicity data are available from studies conducted on experimental animals, with effects having been identified on hepatotoxicity and the immune and developmental systems, as well as concerning increased mortality, hormonal effects and a carcinogenic potency [2, 5, 13, [17] [18] [20] [21] [22] . In humans, possible post-exposure effects could be related to different cancer types and the reproductive, developmental and hormone systems [5, [23] [24] [25] .
In order to investigate human exposure to chemical substances, human biomonitoring (HBM) is used as a tool for exposure assessment, with assessments of PFASs exposure being mainly conducted on blood samples [1, 5, [13] [14] 20, [26] [27] [28] [30] [31] . PFASs were also investigated in other human media such as breast milk [14, 20, 29] . However, investigations of the occurrence of specific PFASs in human urine are comparably rare [30] [31] [32] [33] [34] [35] [36] [37] .
For the present study we adapted a sensitive analytical method for the measurement of several PFASs in human urine with a primary focus on short-chain PFASs. Furthermore, we also conducted a pilot study with 11 participants in order to verify the analytical method.
Materials and methods

Chemical analysis
The chemical analysis of 12 PFASs compounds in human urine was performed by high-performance liquid chromatography tandem-mass spectrometry (HPLC-MS/MS) for simultaneous determination based on an analytical method published in Zhang et al. [35] . PFASs compounds included in the analysis and the internal and external standards which were used are listed in Table 1 .
To avoid potential contamination of the samples during sample preparation, all glass equipment was pre-treated with methanol and water and heated at 300°C for 24 hours. Solvents were distilled, and all water used was filtered by an Oasis HLB-column (6cc Cartridge 500 mg) (Waters Corporation, Milford, MA, USA) and cartridges (Oasis Wax 6cc Vac Cartridge, 500 mg sorbent, 60 µm particle size and Oasis Wax 6cc Vac Cartridge, 150 mg sorbent, 30 µm particle size) (Waters Corporation, Milford, MA, USA). Additionally, for the minimisation of matrix effects during HPLC analysis, an additional clean-up of the solid-phase extraction (SPE) eluates was performed with charcoal.
For sample preparation, 50 ml of urine sample were weighted in polypropylene tubes (Sarstedt, Nümbrecht, Germany) and 1 ng of the internal standard solution was added. 50 g of filtered tap water were used for the preparation of blanks. For additional quality assurance, sample container blanks were prepared. For recovery control, the native standard solution was added to samples at two concentration levels (10 and 25 ng/l) and to blanks at a single concentration level (10 ng/l). After centrifugation for 20 minutes at 4,700 rpm, samples were applied to cartridges (Oasis Wax 6cc Vac Cartridge, 150 mg sorbent, The limits of quantification (LOQ) and limits of detection (LOD) of the investigated PFASs are listed in Table 1 . The LODs were set as 40% of the respective LOQs. The mean relative recoveries for the different PFASs were calculated based on spiked samples (n=32) and ranged between 56±12% and 74±9%.
Creatinine analysis
Due to the possibility of urine concentrations or urine dilution affecting concentrations of analytes and due to variable creatinine production during different life stages [19] , creatinine adjustment was performed for the correction of these variations. Creatinine concentrations of the urine samples provided were analysed by an external medical laboratory via a photometric method by Roche/ Hitachi cobas c 701 analyser (Roche Diagnostics, USA). 
Study design and study population
For verification of the analytical method adapted for urinary PFASs analysis, a pilot study was conducted. Participants were recruited in August 2016 and included 11 staff members of the Environment Agency Austria (EAA). Before inclusion in the pilot study, participants had to sign an informed consent. Urine samples (first morning void) were collected from all participants and were stored at -20°C at the EAA laboratory until analysis. Questionnaires were provided to survey personal information (e.g. age, sex), health, lifestyle (e.g. use of functional sportswear), working place, living place and nutrition including a food frequency questionnaire for the previous two months as well as for the last three days before sampling to potentially find possible indications of statistical associations and/ or differences between the surveyed parameters and the PFASs exposure. In total, 11 healthy staff members comprising 6 males and 5 females aged 25-46 years were included in the pilot study. Details on the study population are given in Table 2 .
Statistical analysis
Statistical analysis was conducted using IBM ® SPSS ® Statistics Version 21. Descriptive statistics including ranges, medians, means and corresponding standard deviations were determined for unadjusted urinary PFASs concentrations (expressed in ng/l urine) and for creatinine-adjusted urinary PFASs concentrations (expressed in ng/g creatinine). For data treatment, PFASs levels below the LOQ were set to LOQ/2, and levels <LOD were set to zero. Urinary PFASs levels were tested for their normal distribution with a Kolmogorov-Smirnov test. For the investigation of correlations between the different PFASs concentrations, Pearson tests were used for normal distributed data and Spearman's rank tests for data which were not normally distributed. For the statistical analysis of differences between groups (e.g. sex), Mann-Whitney U and Kruskal-Wallis tests were used depending on the type of data. Values of p < 0.05 were considered for the indication of statistical significance.
Results and discussion
The concentrations of a total of 12 PFASs in 11 first morning void urine samples of male and female adults are shown in Table 3 -in ng/l for unadjusted levels and in ng/g for creatinine-adjusted levels. The compounds PFHxA, PFOA, PFOS and PFNA were found in all urine samples investigated in concentrations (unadjusted) ranging between <LOQ-3.0 ng/l (median: 1.5 ng/l), 0.79-5.1 ng/l (1.9 ng/l), <LOQ-4.9 ng/l (1.6 ng/l) and <LOQ-0.57 ng/l (<LOQ), respectively. In 72.7% of the urine samples, PFPeA and PFHxS were detected at levels of n.d. Figure 1 shows the graphical distribution of investigated PFASs detectable in the urine samples for unadjusted and creatinine-adjusted concentrations, respectively.
No statistically significant differences and/or associations were found between urinary PFASs exposure 
Abbreviations: DR, detection rate; n, number of analysed samples; n.d., not detectable; LOQ, limit of quantification; SD, standard deviation. and age, sex, the use of potentially PFASs-containing products such as functional sportswear, baking parchment or non-stick cookware, weight loss, or the consumption of microwave popcorn or fish. Statistically significant correlations could be identified between unadjusted PF6C and PF8C levels (r=0.764) as well as between creatinineadjusted PF8C and PF9C levels (r=0.782) at a significance level of 0.01. However, it is important to note that the low sample size is very likely to be insufficient for the determination of statistically significant differences and/ or associations. Only a few studies have investigated PFASs exposure in human urine (see Table 4 ). Harada et al. estimated urinary PFOA and PFOS concentrations in 48 adults from Japan based on 24-hour urine samples, which were found in all samples in concentrations ranging between 8.7 and 39 ng/d (median: 8.6 ng/d) and between 1.4 and 36 ng/d (9.9 ng/d), respectively [32] . A study conducted in a medical researcher from Canada in 2007 analysed seven different PFASs in urine, finding that only PFOA was detectable at a concentration of 3,720 ng/l [33] . Zhang et al. analysed several PFASs in urine samples of 86 Chinese adults. PFOS and PFOA were found in all investigated samples with the highest concentration of 1,040 ng/l found for PFOA. The detection rates for the other compounds analysed ranged between 67% (PFHxA) and 98% (PFHxS and PFUnDA) [34] . An investigation of PFOS and PFOA in urine samples from Chinese adults aged 22-62 years in 2010 showed exposure levels of n.d.-296 ng/l (median: < 4 ng/l) for PFOS and of n.d.-41 ng/l (9.0 ng/l) for PFOA with detection rates of 48% and 76%, respectively. In the same study, the investigation of pregnant women aged 21-39 years showed urinary exposure to PFOS of n.d.-132 ng/l (median: < 4 ng/l) and of PFOA of n.d.-30 ng/l (< 4 ng/l) with detection rates of 11% for PFOS and of 30% for PFOA [35] . In a study conducted in 2012 of children aged 5-13 years and adults aged 20-29 years from South Korea, urinary exposure to a total of 15 PFASs was investigated. Most compounds were not detectable or only detectable in frequencies of 1%. PFPeA, PFHxA and PFHpA were found in 11% (PFHxA) to 70% (PFPeA) of urine samples of children, with the highest concentration being found for PFPeA at 11,600 ng/l. In adults, the named substances were analysed in 5% (PFHxA) to 25% (PFPeA) of the investigated samples, with the highest maximum concentration within this population group reaching 17,600 ng/l for PFPeA [36] . Li et al. analysed urinary PFOS and PFOA exposure levels in 63 Chinese adults aged 19-43 years. They reported PFOS concentrations in urine of up to 160 ng/l (median: 37 ng/l) in 95% of the investigated samples, and PFOA concentrations of up to 57 ng/l (8.0 ng/l) in 56% of the samples [37] . As shown in Table 4 , results of PFASs levels measured in human urine are highly variable in different investigations. For example, the median concentrations of PFOS and PFOA ranged in different studies from n.d. [33, 36] to 37 ng/l [37] and n.d. [36] to 3,720 ng/l [33] , respectively. A possible explanation for these variations could be different lifestyles and nutrition, such as different consumption frequencies of contaminated fish and seafood in the different populations.
For the majority of the available studies, long-chain PFASs were not detectable or were found only in low concentrations. This is in concordance with findings from the present study, where PFASs with chain-lengths of > 10 could not be detected in any of the investigated samples. These findings support the assumption that compounds with longer chain length are not well metabolised [13] , bind to serum proteins and accumulate in the body [14, 15] . Additionally, studies have shown that urinary excretion decreases with increasing chain length [15] .
Compared with the results of previous studies, PFASs concentrations in the present pilot study were notably lower. However, because of the small sample size investigated in the present study, comparisons should be conducted with care.
Conclusions
A sensitive analytical method was adapted for the analysis of PFASs in human urine by HPLC-MS/MS. The method was employed to analyse urine samples of 11 EAA employees to test the analytical method.
PFASs with chain lengths of 5 to 9 carbon atoms were detectable in the investigated urine samples with detection frequencies between 72.7% and 100%. The highest concentration was found for PFPeA (C5), reaching 8.5 ng/l in one sample. Compounds of chain lengths from 10 to 12 carbon atoms were not found in any of the samples. No differences in PFASs exposure with respect to age or sex were identified. However, the sample size was too small to allow for statistically significant conclusions.
The adaption of a sensitive analytical method for PFASs analysis in human urine and its application within a small pilot study shows that especially short-chain PFASs can be found in urine, which is also in accordance with findings of previous studies.
The measurement of PFASs in urine enables the study of exposure within populations thus so far only infrequently investigated, such as infants and children. It further facilitates the investigation of dietary habits and allows for the identification of sources of PFASs. 
